ArticleTranslational cancer research2025
N6-adenosine methyltransferase METTL4 is a potential prognostic biomarker and associates with cell cycle regulation and immune infiltration in glioma.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Molecular typing is the hope for overcoming brain glioma in the future. METTL4 belongs to the MT-A70 family of methyltransferase proteins and mediates N6-adenosine methylation for both RNA and DNA in eukaryotes. METTL4 has recently been identified to participate in tumorigenesis, but the relation between METTL4 and glioma has not been revealed yet. The aim of this study was to identify METTL4 as a potential biomarker and therapeutic target for predicting the prognosis of glioma. Methods: This study assessed the clinical significance and prognostic value of METTL4 in glioma using data from The Cancer Genome Atlas (TCGA) database. Data from TCGA and Chinese Glioma Genome Atlas (CGGA) databases were used for correlation analysis of METTL4, and the genes that were most related to METTL4 were analyzed using the Database for Annotation, Visualization, and Integrated Discovery (DAVID) database for Gene Ontology (GO) enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis. Protein-protein interaction (PPI) networks and functional interactions between proteins were analyzed using the Search Tool for the Retrieval of Interacting Genes (STRING) database. Key pathways associated with METTL4 were revealed through gene set enrichment analysis (GSEA). The correlation between METTL4 and tumor immune infiltration was investigated by single-sample gene set enrichment analysis (ssGSEA) of TCGA data. Moreover, the expression of METTL4 was detected through Western blotting. Cell cycle regulation and mitochondrial reactive oxygen species (ROS) were measured by flow cytometry. Results: High expression of METTL4 was associated with a poorer prognosis of glioma patients and METTL4 was an independent prognostic factor for overall survival (OS). Differentially expressed gene (DEG) analysis and GSEA revealed that METTL4 was closely related to cell cycle and immune infiltration. Knockdown of METTL4 induced G0/G1 arrest and higher mitochondrial ROS levels, but there was no significant change in the rate of apoptosis. Conclusions: All findings indicated that METTL4 was a potential prognostic biomarker correlated with cell cycle and immune infiltration in glioma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.